Champions Oncology (CSBR) Shares Outstanding (2011 - 2026)
Champions Oncology (CSBR) posted quarterly Shares Outstanding (Entity) of $14.0 million for Q2 2026, up 0.79% year-over-year from $13.9 million in Q2 2025, and little changed quarter-over-quarter from $14.0 million in Q1 2026.
Champions Oncology (CSBR) Shares Outstanding (2011 - 2026) Analysis & Trends
Champions Oncology's Shares Outstanding (Entity) history runs 16 years deep, the most recent figure standing at $14.0 million for Q2 2026.
- In Q2 2026, Shares Outstanding (Entity) rose 0.79% year-over-year to $14.0 million; the TTM figure through Apr 2026 stood at $14.0 million (up 0.79% YoY), while the FY2026 annual figure was $14.0 million, up 0.79% from the prior year.
- Shares Outstanding (Entity) for Q2 2026 stood at $14.0 million, roughly flat from $14.0 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $14.0 million in Q1 2026, with the low at $13.5 million in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $13.7 million (2023), against an average of $13.7 million.
- The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Entity) rose 0.27% in 2023, then grew 1.42% in 2025.
- Champions Oncology's Shares Outstanding (Entity) stood at $13.6 million in 2022, then rose by 1.15% to $13.7 million in 2023, then increased by 0.77% to $13.8 million in 2024, then advanced by 1.36% to $14.0 million in 2025, then grew by 0.0% to $14.0 million in 2026.
- Business Quant data shows CSBR's Shares Outstanding (Entity) at $14.0 million in Q2 2026, $14.0 million in Q1 2026, and $14.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 133.61 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 217.35 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 445.06 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 241.70 Mn |
| 10 | Champions Oncology | 71.17 Mn | 71.17 Mn | 7.03 Mn | 13.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 13.83 Mn |
| Jan 31, 2026 | 13.89 Mn |
| Oct 31, 2025 | 13.79 Mn |
| Jul 31, 2025 | 13.79 Mn |
| Apr 30, 2025 | 13.66 Mn |
| Jan 31, 2025 | 13.70 Mn |
| Oct 31, 2024 | 13.59 Mn |
| Jul 31, 2024 | 13.59 Mn |
| Apr 30, 2024 | 13.55 Mn |
| Jan 31, 2024 | 13.59 Mn |
| Oct 31, 2023 | 13.50 Mn |
| Jul 31, 2023 | 13.51 Mn |
| Apr 30, 2023 | 13.54 Mn |
| Jan 31, 2023 | 13.56 Mn |
| Oct 31, 2022 | 13.53 Mn |
| Jul 31, 2022 | 13.52 Mn |
| Apr 30, 2022 | 13.20 Mn |
| Jan 31, 2022 | 13.50 Mn |
| Oct 31, 2021 | 13.43 Mn |
| Jul 31, 2021 | 13.40 Mn |